Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics Inc (RNAZ) is a clinical-stage biopharmaceutical company pioneering RNA-based therapies for metastatic cancers through its proprietary TTX nanoparticle delivery platform. This news hub provides investors and researchers with essential updates on the company’s progress in developing targeted treatments, including its lead candidate TTX-MC138 designed to inhibit metastasis-driving microRNA-10b.
Our curated collection offers immediate access to official press releases, clinical trial milestones, and strategic partnership announcements. Users will find updates spanning multiple critical areas: TTX platform advancements, regulatory submissions, financial disclosures, and peer-reviewed research collaborations in oncology.
Key content includes developments around the company’s nanoparticle delivery system, trial results for metastatic cancer therapies, and analyses of RNAZ’s position within the competitive oncology therapeutics market. All materials are sourced directly from company filings and verified industry publications to ensure reliability.
Bookmark this page for streamlined tracking of TransCode’s innovations in RNA oncology. Check regularly for new insights into how the company’s cutting-edge approach to metastatic disease treatment continues to evolve through clinical validation and strategic execution.
TransCode Therapeutics (NASDAQ: RNAZ) has regained compliance with Nasdaq's listing standards, ensuring its stock remains on the exchange. The scheduled hearing for June 25, 2024, has been cancelled. The company will be monitored by Nasdaq until January 26, 2025. This compliance follows recent positive developments, including favorable blood test results from a Phase 0 clinical trial and FDA approval to proceed with a Phase 1 study. TransCode's leadership indicates that with the current share price above the $1.00 minimum bid, a reverse split is not anticipated.
TransCode Therapeutics (NASDAQ: RNAZ) announced positive preliminary data from its Phase 0 clinical trial for TTX-MC138, their lead RNA-based therapeutic candidate. The trial showed significant inhibition of the molecular target miRNA-10b, with a 66% reduction in the patient's blood 24 hours post-administration. This inhibition is linked to complete regressions of metastatic disease in animal models. The study also revealed effective delivery of TTX-MC138 to metastatic tumors and no adverse events were observed, indicating the treatment's safety at a microdose. These findings support further clinical development, with a Phase 1 study planned to explore TTX-MC138's potential for treating multiple metastatic cancers.
TransCode Therapeutics issued an open letter to shareholders regarding a proposed reverse split of their stock due to not meeting the Minimum Bid Requirement. The company faces potential delisting from Nasdaq but intends to appeal the decision. They believe a reverse split is the best chance to maintain Nasdaq listing. The Board and Management express their reluctance but emphasize the importance of shareholder support.
FAQ
What is the current stock price of Transcode Therapeutics (RNAZ)?
What is the market cap of Transcode Therapeutics (RNAZ)?
